| 1 |
33731883 | Pharmacogenetic-guided glimepiride therapy in type-2 diabetes mellitus: a cost-effectiveness study. | 2021 Oct |
4 |
| 2 |
34727989 | Hypoglycemia possibly caused by CYP2C9-mediated drug interaction in combination with bucolome: a case report. | 2021 Nov 3 |
2 |
| 3 |
30030468 | CYP2C9 and OATP1B1 genetic polymorphisms affect the metabolism and transport of glimepiride and gliclazide. | 2018 Jul 20 |
5 |
| 4 |
26569597 | Metabolic Interaction Potential between Clopidogrel and Sulfonylurea Antidiabetic Agents: Effects on Clopidogrel Bioactivation. | 2016 |
3 |
| 5 |
24118918 | In vitro assessment of 36 CYP2C9 allelic isoforms found in the Chinese population on the metabolism of glimepiride. | 2014 Apr |
3 |
| 6 |
24799741 | Investigating the Role of Plasma Glucose Concentration as a Phenotypic Marker for CYP2C9 Genetic Variants, in the Diabetic Population of Gujarat. | 2014 Jan |
2 |
| 7 |
24986093 | Drug-drug interaction of losartan and glimepiride metabolism by recombinant microsome CYP2C9*1, 2C9*3, 2C9*13, and 2C9*16 in vitro. | 2014 Sep |
21 |
| 8 |
21208246 | Frequency of CYP2C9 variant alleles, including CYP2C9*13 in a Korean population and effect on glimepiride pharmacokinetics. | 2012 Feb |
2 |
| 9 |
22360448 | Rosuvastatin suppresses the liver microsomal CYP2C11 and CYP2C6 expression in male Wistar rats. | 2012 Aug |
1 |
| 10 |
23156991 | Effect of piperine on the pharmacokinetics and pharmacodynamics of glimepiride in normal and streptozotocin-induced diabetic rats. | 2012 Oct |
3 |
| 11 |
21476064 | Population pharmacokinetic analysis of glimepiride with CYP2C9 genetic polymorphism in healthy Korean subjects. | 2011 Sep |
7 |
| 12 |
20698928 | Potential CYP2C9-mediated drug-drug interactions in hospitalized type 2 diabetes mellitus patients treated with the sulphonylureas glibenclamide, glimepiride or glipizide. | 2010 Oct |
5 |
| 13 |
21121772 | Effect of CYP2C9 polymorphisms on prescribed dose and time-to-stable dose of sulfonylureas in primary care patients with Type 2 diabetes mellitus. | 2010 Nov |
1 |
| 14 |
19541829 | Substrate-dependent functional alterations of seven CYP2C9 variants found in Japanese subjects. | 2009 Sep |
7 |
| 15 |
19891554 | Presence of CYP2C9*3 allele increases risk for hypoglycemia in Type 2 diabetic patients treated with sulfonylureas. | 2009 Nov |
3 |
| 16 |
16325295 | Effect of CYP2C9 genetic polymorphisms on the efficacy and pharmacokinetics of glimepiride in subjects with type 2 diabetes. | 2006 May |
12 |
| 17 |
16946524 | Effect of glimepiride and glibenclamide on S-warfarin 7-hydroxylation by human liver microsomes, recombinant human CYP2C9.1 and CYP2C9.3. | 2006 Sep |
7 |
| 18 |
16372821 | Effect of genetic polymorphisms in cytochrome p450 (CYP) 2C9 and CYP2C8 on the pharmacokinetics of oral antidiabetic drugs: clinical relevance. | 2005 |
1 |
| 19 |
12235454 | Glyburide and glimepiride pharmacokinetics in subjects with different CYP2C9 genotypes. | 2002 Sep |
3 |
| 20 |
11309547 | Effects of fluconazole and fluvoxamine on the pharmacokinetics and pharmacodynamics of glimepiride. | 2001 Apr |
1 |
| 21 |
11719730 | Effect of gemfibrozil on the pharmacokinetics and pharmacodynamics of glimepiride. | 2001 Nov |
2 |
| 22 |
11136298 | Effect of rifampicin on the pharmacokinetics and pharmacodynamics of glimepiride. | 2000 Dec |
2 |